Recently diagnosed with HIV? Click here

Lersivirine long term safety study

Clinical trial • Not yet started • 25 March 2011
This trial has not yet started – enrolment for this trial has not yet commenced. Depending on eligibility, you may be able to enrol in this trial at a later date.

About this trial

This is a study to assess long-term safety and efficacy(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of lersivirine in people who have already completed 96 weeks of treatment with lersivirine in studies A5271015 and A5271022.

Official title:A Long Term Open-Label Extension Study of Lersivirine For The Treatment Of HIV-1 Infection
What is this trial studying?New drug – efavirenz, etravirine (TMC-125), UK-453,061
Start date:March 2011

This may be the proposed or expected start date for trials which have not yet started.

How long is this trial planned to go for?Participants in this trial will be asked to take the trial drugs for 240 weeks.
Links to further information:
Related trials:

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least years old
  • Viral load below 50 copies/ml
  • Patients must complete of 96 weeks of treatment with lersivirine (or comparator where required by local regulation) in one of the parent protocols (A5271015 or A5271022).

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

If you are interested in enrolling in this trial

Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • You can print this page to take it with you to the doctor – just use your browser's 'print' function.
  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 25 March 2011 — more than one year ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more